Shall we treat smoldering multiple myeloma in the near future?
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
In recent years, several new drugs have been approved for the treatment of multiple myeloma. Many of these newer drugs are highly efficacious and less toxic than older chemotherapy drugs. In 2014, the diagnostic criteria for multiple myeloma were revised. The intent with the new criteria was to identify patients who require therapy at an earlier stage than at manifestation of organ complications. A subset of patients who were previously defined as having high-risk smoldering multiple myeloma was redefined as having multiple myeloma. In this context, it is logical to raise questions regarding the optimal clinical management of patients who are diagnosed with smoldering multiple myeloma in the current era. When is the optimal time to start therapy? Do the clinical trajectories for patients suggest there are distinct sub-entities hidden in the current category of smoldering multiple myeloma? How can we move the field forward from here? This paper reviews and dissects data and models on the topics of clinical features, underlying biology, and early treatment trials in smoldering multiple myeloma. The text highlights assumptions, facts, and gaps in the literature. As indicated in the title of the paper, the recurrent theme of the text is this: shall we treat smoldering multiple myeloma in the near future?
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationLenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171 · cited 3×
“Based on these results, the authors conclude that early treatment of patients with high-risk smoldering myeloma delays progression to active disease and increases overall survival.(44) In a subsequent follow-up study, the authors reported a median follow-up for surviving patients of 75 months, and lenalidomide plus de…”
BackgroundResultInfluentialLandgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194241 · Cited by 1,127 · cited 1×
“In 2009, the prospective PLCO cancer screening study, which included over 77 000 participants with up to 10 years of follow-up, identified 71 individuals who stored baseline samples and who subsequently developed multiple myeloma; all of these individuals had detectable abnormal serum proteins in their baseline sample…”
BackgroundSelf-citationWidespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.015 · Cited by 988
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921 · cited 6×
“The reason they were labeled as having smoldering multiple myeloma is because they had 10% or more plasma cells in their bone marrow and/or they had M protein of at least 3 g per deciliter in the serum.(6) If there were better markers to designate these individuals to the MGUS category (instead of smoldering multiple…”
BackgroundMethodInfluentialPérez-Persona, E., Vidriales, M.-B., Mateo, G., García-Sanz, R., Mateos, M.-V., de Coca, A. G., Galende, J., Martín-Nuñez, G., Alonso, J. M., de las Heras, N., et al. (2007) · Blood · doi:10.1182/blood-2007-05-088443 · Cited by 579
Rajkumar, S. V., Gupta, V, Fonseca, R., Dispenzieri, A., Gonsalves, W. I., Larson, D., Ketterling, R. P., Lust, J. A., Kyle, R. A., & Kumar, S. K. (2013) · Leukemia · doi:10.1038/leu.2013.86 · Cited by 239
Neben, K., Jauch, A., Hielscher, T., Hillengass, J., Lehners, N., Seckinger, A., Granzow, M., Raab, M. S., Ho, A. D., Goldschmidt, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4923 · Cited by 233
Hjorth, M., Hellquist, L., Holmberg, E., Magnusson, B., Rödjer, S., & Westin, J. (1993) · European Journal of Haematology · doi:10.1111/j.1600-0609.1993.tb00148.x · Cited by 220
Cited by
Boyle, E. M., Deshpande, S., Tytarenko, R., Ashby, C., Wang, Y., Bauer, M. A., Johnson, S. K., Wardell, C. P., Thanendrarajan, S., Zangari, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20524-2 · Cited by 128
“Mutations in DIS3 (n= 3), CCND1 (n= 2), and ATM (n= 1), as well as the t(4;14) were associated with the IMWG definition of high-risk.”
BackgroundInfluentialSelf-citationLandgren, O., Hofmann, J. N., McShane, C. M., Santo, L., Hultcrantz, M., Korde, N., Mailankody, S., Kazandjian, D., Murata, K., Thoren, K., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1568 · Cited by 103
Self-citationLandgren, C. O., Chari, A., Cohen, Y. C., Spencer, A., Voorhees, P., Estell, J. A., Sandhu, I., Jenner, M. W., Williams, C., Cavo, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0718-z · Cited by 102
Dutta, A. K., Alberge, J.-B., Lightbody, E. D., Boehner, C. J., Dunford, A., Sklavenitis-Pistofidis, R., Mouhieddine, T. H., Cowan, A. N., Su, N. K., Horowitz, E. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0482 · Cited by 41
Metadata
- Authors
- Landgren, O.
- Venue
- Hematology
- Publisher
- American Society of Hematology
- Published
- 2017-12-08
- Volume
- 2017
- Issue
- 1
- Pages
- 194-204
- ISSN
- 1520-4383 (ISSN-L)
- 1520-4391
- OpenAlex
- W2783177883
- Cited by
- 35
- References
- 9
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.